TM
PTGX icon

Torren Management’s Protagonist Therapeutics PTGX Stock Holding History

Torren Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.68K Hold
30
– – ﹤0.01% 414
2026
Q1 		$3.16K Sell
30
-9
-23% -$797 ﹤0.01% 431
2025
Q4 		$3.41K Buy
+39
New +$3.19K ﹤0.01% 977

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Torren Management's PTGX Position: Q2 2026 in Review

Torren Management held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 30 shares worth $3.68K. The position accounts for ﹤0.01% of the portfolio, ranked #414.

Torren Management first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 134 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Torren Management held 30 shares of Protagonist Therapeutics worth $3.68K as of Q2 2026.
  • Torren Management left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #414 holding.
  • Torren Management first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 134 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.